Margin Farm Health
MarginFarmers believe a purely monetary driven Health Care Industry will always lead to corruption. Conflicts of interest have been built into so many pillars of our economy, Americans are numb to the global impact of our monetary policies.
Since the Federal Reserve chooses which drug companies to finance, its important to reduce the power of this private entity.
Unfortunately, the big business is monetizing people’s fear of death and managing symptoms instead of curing the root cause of the diseases.
Why are we disappointed in our leaders, from both sides of the isle? Because the banks will only finance Health Care Businesses that put corporate profits ahead of the needs of the customers they serve.
See Margin Farm’s top picks for companies that are bringing innovation into this troubled vertical.
Health Cure or Health Care?
A stunning Bloomberg article analyzed whether Gilead Sciences (NASDAQ:GILD) made the right business decision in producing a drug that cured diseases rather than managing them. The perception exists that big pharma companies should focus primarily focus on revenue generation rather than medical breakthroughs.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions.
The Huffington Post article highlights that Health care spending consumes one-fifth of GDP. While health care does create jobs, it also takes jobs away by reducing spending for other public goods: housing, education, and infrastructure. Health care costs bankrupt patients, choke small businesses, contribute to stagnate wages, and force governments at all levels to trim public services.
In short, neither the president’s budget nor Congressional proposals will solve our health care spending crisis. This is a systemic issue when you make health a “monetary” driven industry and put corporate profits ahead of the patients needs.
Margin Farm loves the potential for robotic exoskeletons
Samsung GEMS-H, the South Korean technology giant unveiled the GEMS-H mobility solutions.
Short for “Gait Enhancing and Motivating System,” mobility-focused Samsung GEMS assists users with walking and can also help them strengthen their muscles as well as improve their mobility and balance.
The GEMS-H is a lower-body exoskeleton that is light enough to be comfortable to wear and has an attractive design.
The product won the “Best Accessibility Tech” award at CES.
Margin Farm is a fan of companies pursuing gene therapy.
Uniqure (QURE) “Our mission at uniQure is to deliver curative gene therapies that transform the lives of patients.”
Vision: “Our vision at uniQure is to build an industry-leading, fully integrated and global company that leverages its validated technology and manufacturing platform to deliver trans-formative gene therapy products to patients with serious unmet medical needs.”
Values:
Be passionate about the patient.
Act with integrity and respect.
Take ownership and act with urgency.
Collaborate for success.
Innovate every day.
Focus relentlessly on quality.
VRHealth
According to Eran Orr, CEO, VRHealth, virtual reality (VR) will be a game changer for the healthcare market in three years.
By 2017, MarketsandMarkets.com reported that the VR healthcare market had grown to $976 million from $525 million in 2012. And, according to Grand View Research, the VR and Augmented Reality (AR) healthcare industry will be $5.1 billion by 2025.
Orr's company, VRHealth, an Israeli health tech company based in Boston, announced a partnership on September 27, 2018, with Oculus to bring their newest health and wellness solutions using a range of Oculus products to the healthcare industry.
Organovo: Bio Printing
The company, headquartered in San Diego, California, has been at the forefront of 3D bioprinting research for some time now. Not only are they currently bringing revenues in by providing pharmaceutical companies with their exVive3D™ Liver Tissue for drug toxicity testing, but they have partnered with major companies in the health space including L’Oréal and Merck, and are planning on introducing their exVive3D™ Kidney Tissue product by next year.
With an ultimate goal of 3D printing patches made of human tissue for failing organs, and eventually entire organs for transplantation, Organovo certainly has their work cut out for them.
23andMe.com
The right routine starts with the right data.
Don’t just track your health, hack your health with insights from your DNA.
Experience your ancestry in a new way!Get a breakdown of your global ancestry by percentages, connect with DNA relatives and more.
What are the benefits of IoMT* & who is leading the way?
Noteworth, a connected health platform that enables health organizations to prescribe virtual care models to their patients. They help clinicians collect and access contextualized patient-generated health data that improve care coordination and outcomes, reduces costs, and better engages patients.
The benefits of introducing IoMT are vast, and certainly, there are even more benefits to be discovered as we continue to grow our expertise in this space as an industry.
* IoMT: Internet of Medical Things
Cerebro offers a solution: a faster, responsive healthcare labor marketplace — one that connects healthcare facilities with verified, ready-to-work clinicians. Specifically, Cerebro offers acute care facilities:
Faster fill times. Clinicians on the Cerebro platform use a mobile app which enables them to find and request shifts. It’s fast and easy. The app also uses AI to notify clinicians of new assignments that are an especially good fit.
Higher fill rates. Clinicians on Cerebro can expect to pay up to 30% more than with staffing agencies because Cerebro takes a smaller commission than traditional agencies. Hence Cerebro can attract a larger pool of talented clinicians.
3. Staffing Flexibility. Fill for 1 shift, 1 week, or 1 month. Cerebro does not require minimum contract times. Hospitals find the staff they need when they need it; clinicians work the hours they want when they want it.
Canopy Growth Group
MarginFarm is in awe of what Canopy has been able to do even though the federal head winds have been a CAT 5 hurricane for nearly more than 100 years.
Canopy is advancing the world’s perception of cannabis and removing the false stigmas that have been repeated by our government and health “businesses”.
Through owned and partnered cannabis production platforms, as well as education to help customers safely, effectively and responsibly use cannabis, Canopy has created a dominant, global business with the potential to generate a significant and sustained return on shareholder capital over the long-term.
MarginFarm loves technology and its ability to transform our Health Care Industry to a resource driven, health services for all solution.
In addition to technology helping us evolve, methodology is also evolving and one of our favorites is Egoscue.
FarmerPrenuers Wanted
If you would like to have your solution considered to be a featured solution to other MarginFarmers, we would love to meet you. Feel free to send additional content to mypicks@marginfarm.com.
MarginFarm Originals:
What do you get when you combine the resources of Canopy Growth Group, Amazon, Department of Health and the Department of Education?
You have a generation of kids that are fed healthy food that eliminates the need for them to take ADHD and other prescribed poisons.
We must eliminate the conflict of interest and corruption in the Private Health Care industry. Humans have evolved enough to understand why we are subject to this tyranny but they have not been empowered to make trans-formative change.
